AI Insight
A target trial emulation study examined the safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) medications when continued into early pregnancy. The research found no substantial evidence of increased risk for pregnancy loss, abnormal fetal growth, or major birth defects among women who continued using GLP-1RAs during the first trimester compared to those who discontinued use.
Why it matters
This finding provides important preliminary safety data for women using GLP-1RA medications for diabetes or weight management who become pregnant. The results may help inform clinical decision-making about whether to continue or discontinue these increasingly prescribed medications during early pregnancy, though additional confirmatory studies are needed.
A target trial emulation estimated the risks associated with glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure in early pregnancy. The findings did not indicate a substantially increased risk for nonlive birth, abnormal fetal growth, or major congenital malformation with continuation of GLP-1RAs into the first trimester.
Source: Target trial does not suggest major adverse outcomes with early GLP-1 use in pregnancy